Looking Beyond Triple Therapy for the Hepatitis C Non-Responders Population: U.S. and European Physician Expectations and Perceptions About Quadruple Therapy

— A Webinar from Decision Resources

Based on our DecisionBase 2010 report, Hepatitis C Virus Treatment Non-Responders: Hope on the Horizon with the Imminent Introduction of HCV-Targeted Therapeutics, Decision Resources is offering an exclusive webinar entitled Looking Beyond Triple Therapy for the Hepatitis C Non-Responders Population: U.S. and European Physician Expectations and Perceptions About Quadruple Therapy. Because this webinar will feature major report findings, it is ONLY available to purchasers of this report.

Please contact us to learn how you can purchase this report and attend the webinar.

Hepatitis C virus (HCV) is an attractive target for drug developers; more than 25 drug candidates are in Phase II development or beyond representing 9 drug classes. A majority of these classes represent novel mechanisms of action for targeting HCV. About half of patients fail treatment and these HCV treatment non-responders have few options for subsequent treatment. Consequently, an ever-growing portion of HCV-infected patients are sidelined away from treatment and await novel therapies that can effectively treat them. Because the only option for second-line therapy is another round of treatment (with the same therapies that failed the first time) and because of the low relative risk of death associated with HCV, the HCV treatment non-responder patient population has steadily grown larger over time. As a result, tremendous market potential awaits drugs that can demonstrate improved efficacy in the treatment of this HCV patient subpopulation.

This webinar, presented by Decision Resources Analyst Alexandra Makarova, M.D., Ph.D., will answer the following questions:

• Emerging HCV-specific antiviral agents offer improved efficacy in treatment-experienced HCV patients when used in combination with currently available pegylated interferon alpha (peg-IFN-alpha) and ribavirin. What attributes weigh most heavily on physicians’ prescribing decisions for a particular HCV-specific antiviral to a patient who previously failed HCV treatment?
• What attributes of Roche’s Pegasys (peg-IFN-alpha-2a), Merck’s PegIntron (peg-IFN-alpha-2b), Three Rivers Pharmaceuticals’ Infergen and Astellas Pharma’s Advaferon (IFN-alfacon) provoke the greatest dissatisfaction among gastroenterologists? What are the highest unmet needs for treatment of HCV in patients who previously failed HCV treatment?
• What are clinicians’ expectations for a quadruple HCV treatment regimen combining two HCV-specific antiviral agents, peg-IFN-alpha and ribavirin?

Dr. Makarova will conduct a live Q & A session after the presentation.

Registration

Looking Beyond Triple Therapy for the Hepatitis C Non-Responders Population: U.S. and European Physician Expectations and Perceptions About Quadruple Therapy

February 18, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this report and attend the webinar, please contact us using the information below.

Contact Us

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.